{"disease":{"id":"carcinoid-tumors","name":"carcinoid tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT02177773","title":"GA-68 DOTA-TOC of Somatostatin Positive Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":300,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT01619865","title":"Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":223,"lead_sponsor_name":"Sue O'Dorisio","has_results":true},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT07450287","title":"CardioNETPOL National Registry of Carcinoid Heart Disease","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"National Institute of Cardiology, Warsaw, Poland","has_results":false},{"nct_id":"NCT02826928","title":"Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT03622333","title":"Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT02795858","title":"A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT01253161","title":"Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT02575300","title":"Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT04197310","title":"Cabozantinib and Nivolumab for Carcinoid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT01327612","title":"Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT02859064","title":"Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"SCRI Development Innovations, LLC","has_results":true},{"nct_id":"NCT05987176","title":"Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT04276597","title":"Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Excel Diagnostics and Nuclear Oncology Center","has_results":false},{"nct_id":"NCT04602117","title":"ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT02174679","title":"68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT01980732","title":"68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Andrei Iagaru","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}